Back to Investors
P

Pillar

Venture Capital

Portfolio

2

companies


Portfolio companies

PB

Portal Biotech

Portal Biotech delivers single-molecule protein sequencing technology to transform proteomics and drug discovery.

Latent Labs

Latent Labs

Latent Labs builds AI foundation models to make biology programmable.


Recent investments

Series A
£25.5M

The financing will be used to expand technical teams and accelerate the commercialisation of its proteomics platform.

"Portal Biotech’s technology offers unprecedented capabilities in protein identification and characterisation, providing unmatched detail on protein structure and modifications at the single-molecule level on accessible desktop instruments that bring this state-of-the-art characterisation to any lab. These powerful advances are essential for accelerating drug discovery and enhancing diagnostic precision, positioning Portal Biotech as the frontrunner in the race to unlock the full potential of protein sequencing."
— Andy Heron, Co-founder and CEO
Series A
£40.0M

The financing round was co-led by Radical Ventures and Sofinnova Partners to accelerate the development of programmable biology tools.

"Every biotechnology or pharmaceutical company wants to be at the forefront of technology to find the best therapeutic molecules, yet not all are in a position to develop the most advanced AI models for the job. That’s where Latent Labs comes in. We push the frontiers of generative biology, giving our partners instant access to tools that accelerate their drug design programs."
— Simon Kohl, CEO and founder